Clik here to view.
武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据，该试验评估ADCETRIS® (brentuximab...
马萨诸塞州剑桥、日本大阪和华盛顿州博瑟尔 (美国商业资讯) – 武田药品工业株式会社(TSE:4502)和Seattle Genetics, Inc. (NASDAQ: SGEN)今天宣布，3期ECHELON-1临床试验的数据将于2017年12月10日星期天在第59届美国血液学会(ASH)年会的全体科学会议上呈报，该项试验评估ADCETRIS (brentuximab...
View ArticleClik here to view.
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with...
TOKYO, BASKING RIDGE, N.J. & LOS ANGELES Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research...
View ArticleClik here to view.
Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for...
CAMBRIDGE, Mass. Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined...
View ArticleClik here to view.
ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、リンパ腫と白血病の重要な亜型でADCT-402（loncastuximab...
View ArticleClik here to view.
三叶草生物制药完成6,280万元人民币A轮融资
成都 三叶草生物制药，一家致力于创新及变革性生物制药研发的生物制药公司，今天宣布完成6,280万元人民币（约合950万美元）的A轮融资。 结合其他非稀释性资金来源，此次融资将三叶草2017年获得的资金总额达到8,430万元人民币（约合1,270万美元）。此 A轮融资由四川天河生物医药产业创业投资基金作为领投者。...
View ArticleClik here to view.
Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a RMB 62.8 million...
View ArticleClik here to view.
Orthocell Granted European Tendon Regeneration Patent
PERTH, Australia Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a key European Patent. The patent is entitled...
View ArticleClik here to view.
Chi-Med Initiates Fruquintinib U.S. Clinical Trials
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent...
View ArticleClik here to view.
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a...
OSAKA, Japan & LEUVEN, Belgium Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for...
View ArticleClik here to view.
Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho...
NEW YORK Eternity Healthcare (“Eternity” or the “Company”) (OTC: ETAH) today announced that it has entered into a share exchange agreement (the “Exchange Agreement”) dated December 13, 2017, with...
View ArticleClik here to view.
BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
爱德华王子岛夏洛特镇 — (美国商业资讯) — 全球性创新合同开发制造组织(CDMO) BioVectra Inc.今天宣布与Keryx Biopharmaceuticals, Inc.签署长期供货协议，以制造Auryxia®片剂的活性药物成分(API)枸橼酸铁，该片剂获准用于治疗慢性肾病的两种常见并发症。 BioVectra...
View ArticleClik here to view.
武田薬品とシアトル・ジェネティクスが進行期ホジキンリンパ腫のフロントライン治療でアドセトリス（ブレンツキシマブ・ベドチン）を評価する第3相ECHELON-...
米マサチューセッツ州ケンブリッジ & 大阪 & ワシントン州ボセル （ビジネスワイヤ）– 武田薬品工業株式会社（TSE:4502）とシアトル・ジェネティクス（NASDAQ:...
View ArticleClik here to view.
ABEC Expands Vessel Supply and Service Capability for Global...
BETHLEHEM, Pa. ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced its manufacturing facility in Kells, Co. Meath, Ireland has...
View ArticleClik here to view.
Samsung Bioepis’ SB3 Trastuzumab Biosimilar Candidate Accepted for Review by...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) under the 351(k)...
View ArticleClik here to view.
ABEC扩张容器供应和服务能力，以服务全球生物医药制造商
宾夕法尼亚州伯利恒 (美国商业资讯)–为生物制药制造提供一体化解决方案和服务的全球领先提供商ABEC今日宣布，公司设在爱尔兰米斯郡Kells的生产工厂已获得了ASME压力容器制造和服务授权认证。ABEC Kells是爱尔兰首个荣获ASME授权认证的设备制造商。 ASME颁发的授权认证彰显了ABEC对ASME...
View ArticleClik here to view.
Certara: A Proud Member of Medicines Development for Global Health’s (MDGH)...
PRINCETON, N.J. Certara®, the global leader in model-informed drug development and regulatory science, today congratulated Medicines Development for Global Health (MDGH), a not-for-profit global...
View ArticleClik here to view.
Gynesonics Announces Submission of FDA 510k for Incision-Free Treatment of...
REDWOOD CITY, Calif. Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its submission to the FDA of its 510(k)...
View ArticleClik here to view.
Denis DELVAL被任命为LFB SA首席执行官
法国于利斯 (美国商业资讯) — 12月20日，《Le Journal Officiel》*公布了法国总统的一项行政命令，任命Denis DELVAL为LFB S.A.的首席执行官。该命令是在2017年12月4日LFB SA召开全体大会和董事会会议之后颁布。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
ドニ・デルバールをLFBの最高経営責任者に任命
仏レジュリス （ビジネスワイヤ） — 12月20日、ドニ・デルバールをLFBの最高経営責任者（CEO）に任命するフランス大統領令がLe Journal Officiel*に掲載されました。この命令は、2017年12月4日に開催されたLFB株主総会およびLFB取締役会を受けて公布されました。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：...
View ArticleClik here to view.
三叶草生物制药获得CFDA临床批件开始在中国进行依那西普生物类似药SCB-808临床试验
成都 三叶草生物制药，一家致力于创新及变革性生物制药研发的生物制药公司，今天宣布已获得中国食品药品监督管理局（CFDA）颁发的临床批件，在中国进行SCB-808预充填小容量注射液Enbrel®（依那西普）生物类似药的临床试验，用于治疗类风湿性关节炎和其他自身免疫性疾病，预计将在2018年中期进入中国I期临床试验。 三叶草生物制药创始人、董事长及总裁梁朋博士表示：“我们非常高兴获得CFDA...
View Article